Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2008 1
2009 1
2012 1
2013 1
2014 3
2015 2
2017 2
2018 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results.
Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Sarnelli A, Celli M, Fantini L, Moretti A, Galassi R, De Giorgi U, Paganelli G. Matteucci F, et al. Among authors: galassi r. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194. doi: 10.1007/s00259-017-3791-4. Epub 2017 Aug 11. Eur J Nucl Med Mol Imaging. 2017. PMID: 28801787
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis.
Ranallo N, Iamurri AP, Foca F, Liverani C, De Vita A, Mercatali L, Calabrese C, Spadazzi C, Fabbri C, Cavaliere D, Galassi R, Severi S, Sansovini M, Tartaglia A, Pieri F, Crudi L, Bianchini D, Barone D, Martinelli G, Frassineti GL, Ibrahim T, Calabrò L, Berardi R, Bongiovanni A. Ranallo N, et al. Among authors: galassi r. Cancers (Basel). 2022 Jun 30;14(13):3231. doi: 10.3390/cancers14133231. Cancers (Basel). 2022. PMID: 35805003 Free PMC article.
Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.
Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Bongiovanni A, et al. Among authors: galassi r. Onco Targets Ther. 2014 Oct 20;7:1919-26. doi: 10.2147/OTT.S68573. eCollection 2014. Onco Targets Ther. 2014. PMID: 25364262 Free PMC article.
Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report.
Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T. Ricci M, et al. Among authors: galassi r. Future Oncol. 2014 Aug;10(10):1735-9. doi: 10.2217/fon.14.36. Future Oncol. 2014. PMID: 25303054
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P, De Giorgi U, Scarpi E, Fantini L, Moretti A, Galassi R, Celli M, Conteduca V, Rossi L, Bianchi E, Paganelli G, Matteucci F. Caroli P, et al. Among authors: galassi r. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6. Eur J Nucl Med Mol Imaging. 2018. PMID: 29110067 Clinical Trial.
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, Moretti A, Galassi R, Rossi L, Amadori D, Paganelli G, Matteucci F. De Giorgi U, et al. Among authors: galassi r. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1276-83. doi: 10.1007/s00259-015-3042-5. Epub 2015 Mar 26. Eur J Nucl Med Mol Imaging. 2015. PMID: 25808631
14 results